Tags: Diabetes | new | diabetes | drug | green | light | european

New Diabetes Drug Gets Green Light

New Diabetes Drug Gets Green Light
(Copyright DPC)

Friday, 26 January 2018 09:27 AM

A European Medicines Agency (EMA) panel on Friday recommended granting marketing approval to a diabetes drug developed by Merck & Co. and Pfizer Inc.

The recommendation by EMA's Committee for Medicinal Products for Human Use (CHMP) can be a shot in the arm for drug companies as they are normally endorsed by the European Commission.

The oral treatment for Type II diabetes, which will be sold under the brand name Steglatro, belongs to a class of drugs known as SGLT2 inhibitors, which help patients expel excess glucose through urine.(http://bit.ly/2FjyqXs)

In December, Merck and Pfizer won approval from the U.S. Food and Drug Administration for Steglatro as a single therapy and in fixed-dose combinations with Merck's diabetes drug Januvia or with metformin, an older generic treatment typically given to newly diagnosed patients.

Diabetes, characterized by elevated blood sugar levels, can severely damage organs, including eyes and kidneys, and significantly raises the risk of heart attack and stroke.

As type II diabetes progresses, many patients need additional treatments to better control blood sugar levels.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
A European Medicines Agency panel has recommended granting marketing approval to a diabetes drug developed by Merck & Co. and Pfizer Inc.
new, diabetes, drug, green, light, european
172
2018-27-26
Friday, 26 January 2018 09:27 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved